TY - JOUR
T1 - The BiTE (bispecific T-cell engager) platform
T2 - Development and future potential of a targeted immuno-oncology therapy across tumor types
AU - Einsele, Hermann
AU - Borghaei, Hossein
AU - Orlowski, Robert Z.
AU - Subklewe, Marion
AU - Roboz, Gail J.
AU - Zugmaier, Gerhard
AU - Kufer, Peter
AU - Iskander, Karim
AU - Kantarjian, Hagop M.
N1 - Publisher Copyright:
© 2020 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society
PY - 2020/7/15
Y1 - 2020/7/15
N2 - Immuno-oncology therapies engage the immune system to treat cancer. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor-specific antigens, allowing off-the-shelf immuno-oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B-cell non-Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small-cell lung cancer). BiTE molecules with an extended half-life relative to the canonical BiTE molecules are also being developed. Advances in immuno-oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments.
AB - Immuno-oncology therapies engage the immune system to treat cancer. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor-specific antigens, allowing off-the-shelf immuno-oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B-cell non-Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small-cell lung cancer). BiTE molecules with an extended half-life relative to the canonical BiTE molecules are also being developed. Advances in immuno-oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments.
KW - Adolescent
KW - Adult
KW - Antibodies, Bispecific/therapeutic use
KW - Antigens, CD19/immunology
KW - Antigens, Neoplasm/immunology
KW - Antineoplastic Agents/therapeutic use
KW - B-Lymphocytes/immunology
KW - Child
KW - Child, Preschool
KW - Female
KW - Hematologic Neoplasms/therapy
KW - Humans
KW - Immunotherapy, Adoptive/methods
KW - Male
KW - Middle Aged
KW - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy
KW - Receptors, Chimeric Antigen/immunology
KW - T-Lymphocytes/immunology
KW - Treatment Outcome
KW - Young Adult
UR - http://www.scopus.com/inward/record.url?scp=85084451073&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000531899300001&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1002/cncr.32909
DO - 10.1002/cncr.32909
M3 - Review article
C2 - 32401342
SN - 0008-543X
VL - 126
SP - 3192
EP - 3201
JO - Cancer
JF - Cancer
IS - 14
ER -